-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The purpose of the Risks and Benefits of Emergency Rhythm Control in Atrial Fibrillation in Patients with Acute Stroke (RAFAS) trial was to investigate the risks and benefits of early rhythm control in newly documented patients with atrial fibrillation (AF) during acute ischemic stroke
stroke
Recently , a research article was published in JAHA, an authoritative journal in the field of cardiovascular disease.
Vascular diagnosis
The primary endpoint of the study was recurrent acute ischemic stroke within 3 and 12 months
Arrhythmia
Patients (n=300) with AF and acute ischemic stroke (63.
CONCLUSIONS: Early rhythm control strategies in patients with acute ischemic stroke reduced persistent AF and recurrent stroke at 12 months without an increase in composite adverse outcomes
Early rhythm control strategies in patients with acute ischemic stroke reduced persistent AF and recurrent stroke at 12 months without an increase in composite adverse outcomes
Original source:
Junbeom Park.
Risks and Benefits of Early Rhythm Control in Patients With Acute Strokes and Atrial Fibrillation: A Multicenter, Prospective, Randomized Study (the RAFAS Trial)
Leave a Comment